Alzheimer’s Drug on CMS Funding Chopping Block
Many Alzheimer’s patients who rely on a certain type of drug for treatment are in danger of losing federal insurance coverage to fund the cost. Eyewitness News has done several reports on that drug, Aducanumab. The FDA approved it last June but now it could be on the Medicare and Medicaid coverage chopping block.
Watch the story from WBRE-TV in Wilkes-Barre, PA at the link above to learn more about the impact the draft decision could have.
Alzheimer's Association
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia.™ For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.